| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T588 |
0-190 |
Sentence |
denotes |
Based on a query of www.ClinicalTrials.gov, which lists numerous ongoing trials for COVID-19, a number of studies were found that include testing of kinase inhibitors listed in this article. |
| T589 |
191-326 |
Sentence |
denotes |
There are currently several COVID-19 clinical studies investigating imatinib as a single agent (NCT04346147, NCT04357613, NCT04356495). |
| T590 |
327-626 |
Sentence |
denotes |
COVID-19 trials are ongoing that investigate ruxolitinib as a single agent and in combination with the lipid-lowering medication, simvastatin (NCT04348071, NCT04355793, NCT04354714, NCT04362137, NCT04334044, NCT04366232, NCT04338958, NCT04331665, NCT04337359, NCT04361903, NCT04348695, NCT04359290). |
| T591 |
627-1008 |
Sentence |
denotes |
Although there is no strong clinical evidence to date that statins are beneficial for COVID-19 patients and the limited evidence is mixed (156) (157), statins are still under consideration due to possible generation of a greater potent adaptive immune response and a decreased mortality rate associated with patients with influenza, pneumonia, and MERS-CoV (158) (159) (160) (161). |
| T592 |
1009-1259 |
Sentence |
denotes |
COVID-19 clinical studies are investigating baricitinib, both as a single agent and in combination with the antiviral drugs, lopinavir-ritonavir (NCT04340232, NCT04362943, NCT04346147, NCT04358614, NCT04320277, NCT04321993, NCT04345289, NCT04366206). |
| T593 |
1260-1416 |
Sentence |
denotes |
Baricitinib does not interact with antiviral agents due to its prevalent renal elimination, and so it is proposed to suitable for combination therapy (162). |
| T594 |
1417-1682 |
Sentence |
denotes |
There is one study investigating nintedanib, an FGFR (fibroblast growth factor receptor)/PDGFR/VEGFR inhibitor approved for idiopathic pulmonary fibrosis, as a single agent treatment for pulmonary fibrosis in patients with moderate to severe COVID-19 (NCT04338802). |
